Zometa® is effective and well tolerated in the prevention of skeletal related events secondary to metastatic breast cancer treated with hormonal therapy
Year: 2001
Type: article
Source: European Journal of Cancer
Authors: R. Coleman, J. Apffelstaedt, D. Gordon, P. Major, J. Mackey, A. Howell, R. Theriault, Y. Yambros, B. Chen, D. Reitsma
Language: English
Topic: Bone health and treatments
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2034447215